Five Prime Therapeutics (FPRX) Given Media Impact Rating of 0.17

News coverage about Five Prime Therapeutics (NASDAQ:FPRX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5245386961057 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Five Prime Therapeutics stock traded up $0.18 during mid-day trading on Tuesday, reaching $17.24. The company had a trading volume of 75,115 shares, compared to its average volume of 549,671. Five Prime Therapeutics has a 52 week low of $15.66 and a 52 week high of $48.87. The company has a market cap of $600.49, a PE ratio of -3.19 and a beta of 3.41.

How to Become a New Pot Stock Millionaire

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.25. Five Prime Therapeutics had a negative net margin of 380.23% and a negative return on equity of 48.79%. The firm had revenue of $13.22 million during the quarter, compared to the consensus estimate of $9.86 million. analysts forecast that Five Prime Therapeutics will post -4.98 earnings per share for the current year.

A number of brokerages have weighed in on FPRX. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. BidaskClub raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. BMO Capital Markets reduced their price target on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Finally, Nomura reduced their price target on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $47.20.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/04/17/five-prime-therapeutics-fprx-given-media-impact-rating-of-0-17.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply